Biofrontera Inc. (BFRI)
| Market Cap | 10.95M +47.1% |
| Revenue (ttm) | 41.71M +11.7% |
| Net Income | -10.54M |
| EPS | -1.04 |
| Shares Out | 11.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,328 |
| Open | 0.9700 |
| Previous Close | 1.0100 |
| Day's Range | 0.9253 - 1.0100 |
| 52-Week Range | 0.5360 - 1.1900 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 2.75 (+192.55%) |
| Earnings Date | May 14, 2026 |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Financial Performance
In 2025, Biofrontera's revenue was $41.71 million, an increase of 11.75% compared to the previous year's $37.32 million. Losses were -$10.54 million, -40.67% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price target is $2.75.
News
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo...
Biofrontera Earnings Call Transcript: Q4 2025
Record 2025 revenues and Q4 profitability were driven by strong Ameluz sales, a transformative asset acquisition, and a new cost structure. Clinical pipeline advances and expanded IP position set the stage for margin expansion and growth in 2026.
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera (BFRI) Inc., stated: “2025 was a transformational year for Biofrontera. We delivered record annual and fourth quarter revenues, cl...
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of...
Biofrontera reports Phase 2b results of Ameluz PDT in acne vulgaris
Biofrontera (BFRI) announced results of its Phase 2b clinical trial evaluating Ameluz topical gel, 10% PDT for the treatment of moderate to severe acne vulgaris. The multicenter, randomized, double-bl...
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle
Biofrontera reports USPTO decision on Sun Pharma’s challenged claims
Biofrontera (BFRI) announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U....
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), tod...
Biofrontera announces database lock of Phase 1 PK study of Ameluz
Biofrontera (BFRI) announced that the database of its Phase 1 Pharmacokinetics, PK, study evaluating Ameluz topical gel for the treatment of mild to moderate actinic keratoses, AKs, on neck, trunk…
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera announces FDA acceptance of sNDA for Ameluz PDT
Biofrontera (BFRI) announced that the U.S. Food and Drug Administration has completed its filing review and accepted filing of the Company’s supplemental New Drug Application for Ameluz topical gel us...
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of ...
Biofrontera announces positive Phase 3 results for Ameluz PDT
Biofrontera (BFRI) announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz PDT with the red-light LED, or RhodoLED, platform for the treatme...
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Biofrontera and LSL Pharma Group presented at the Lytham Partners 2026 Investor Healthcare Summit, outlining robust revenue growth, margin expansion, and strategic initiatives. Both companies are leveraging acquisitions, product innovation, and market expansion to drive future performance.
Biofrontera reports preliminary Q4 revenue $17M-$17.5M
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera (BFRI), commented “We are very pleased with our fourth quarter performance which was driven by strong execution across the busines...
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Fourth quarter results represent highest quarterly revenue in Company's history Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz ® Full year 2025 revenues also expected to sh...
Biofrontera announces data base locks for two clinical studies
Biofrontera (BFRI) announced the successful database lock of two clinical studies evaluating Ameluz PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026....
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne ...
Biofrontera completes transfer of Ameluz, RhodoLED FDA approval
Biofrontera (BFRI) announced the completion of the transfer of the FDA approvals for Ameluz and the RhodoLED Lamp Series, including the NDA and the Investigational New Drug Application, IND, to…
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
• Ameluz ® and RhodoLED ® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. • Assignment to Biofrontera Inc. of 11 grante...
Biofrontera Inc. files to sell 4M shares of common stock for holders
17:17 EST Biofrontera (BFRI) Inc. files to sell 4M shares of common stock for holders
Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel
Biofrontera (BFRI) announced the completion of the final patient visit in its Phase 1 pharmacokinetic, PK, study of Ameluz gel, 10%, for the treatment of mild to moderate actinic keratoses…
Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2 Completion of this study marks a key milestone towar...